3 completed, 1 active not recruiting, 1 withdrawn. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Piperacillin-Tazobactam: new trials by email Literature Review of Piperacillin-Tazobactam trials Research Report on Piperacillin-Tazobactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2021-09-14 | 2026-04-06 |
| Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics Best Practice, Fecal Microbiota Transplantation, Nystatin - Graft-versus-host Disease Prevention | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-06-01 | 2020-03-04 | |
| Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Cefepime, Ceftolozane, Laboratory Biomarker Analysis - Other Infectious Diseases | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2018-05-16 | 2022-03-15 |
| Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant Piperacillin-tazobactam, cefepime - Intestinal Microbiome, Febrile Neutropenia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 347 | 2017-02-10 | 2026-03-04 |
| Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections ZTI-01, Piperacillin-tazobactam - Urinary Tract Infection Symptomatic, Acute Pyelonephritis | Phase 2 / Phase 3 | Completed | Nabriva Therapeutics AG | 465 | 2016-04-01 | 2019-03-07 |
Febrile Neutropenia (1) · Hematologic Neoplasms (1)
M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (1) · Nabriva Therapeutics AG (1)
United States (5) · Belarus (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Estonia (1) · Georgia (1) · Greece (1) · Hungary (1) · Latvia (1) · Lithuania (1) · Poland (1) · Romania (1) · Russia (1) · Slovakia (1)
Issam I Raad (2) · Amin M Alousi (1) · Evelyn J Ellis-Grosse, PhD (1) · Susan Seo, MD (1)
PMID 30861061, PMID 35663286, PMID 39456544
2015 (1), P30CA016672 (1)